In the pharmaceutical industry, the development of crystallization processes—including for APIs and intermediates, as well as early-stage formulation development—plays a crucial role in the drug development and manufacturing process. Different crystal forms, sizes, and habits can significantly influence the physicochemical properties of a drug, such as dissolution rate, solubility, and stability, and also affect downstream operations during production, such as filtration, drying, grinding, and purification. Therefore, an in-depth study and stringent control of the crystallization process are of utmost importance.

Porton J-Star is a proud gold sponsor of the Pharma Crystallization Summit 2024 (PCS 2024), which will be held on September 26-27, 2024, at Crowne Plaza Hotel, Princeton, New Jersey, USA. Building on the success and essence of the previous four Summits, this year's PCS will once again bring together pioneers in new drug research and development, as well as leading crystallization technology experts and solution providers from both industry and academia. This includes representatives from Pfizer, AbbVie, Amgen, Eli Lilly & Co, Merck, GSK, as well as Carnegie Mellon University, Imperial College, and Rowan University.

In addition to roundtable discussions, this year’s PCS features a new technical solution poster session, offering attendees more opportunities to engage face-to-face with top experts and diverse solution providers in the industry. The conference agenda is extensive, covering core topics throughout the entire drug development lifecycle, from fundamental scientific research to industrial application, aiming to provide efficient technological solutions for challenges at different stages of new drug development. This also helps crystallization and formulation solution providers accurately address industry pain points and efficiently offer customized solutions, jointly driving innovation and development in pharmaceutical crystallization technology.

In collaboration with crystallization experts and CMC leaders from the pharmaceutical industry, academia, and regulatory agencies, the Crystallization Team at Porton, with locations in New Jersey (USA) and Shanghai (China), offers expert services in polymorph discovery and selection, crystallization process development, particle engineering, DS-DP co-processing, and pre-formulation evaluation, and has played a key role in advancing drug development programs globally. The team is dedicated to addressing challenges presented by different forms and supporting a smooth transition through each phase of development and will continue exploring new frontiers in small molecule pharmaceuticals and innovative modalities, providing top-notch services from preclinical to commercial phases.

Early bird registration will close on September 5^th,2024.

Register now to join industry elites at the premier crystallization event!

Registration link: https://crystallizationsummit.com/2024-2/2024-registration/

• Sponsors continually being added
•